A phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy

被引：0
|
作者：
DeWeese, T
Arterbery, E
Michalski, J
Sylvester, JE
Terris, MK
Wilding, G
Yu, DC
Moore, L
Kimball, L
Ando, D
Kim, D
机构：
[1] Johns Hopkins Oncol Ctr, Baltimore, MD USA
[2] Wayne State Univ, Rochester, MI USA
[3] Washington Univ, Med Ctr, St Louis, MO USA
[4] Seattle Prostate Inst, Seattle, WA USA
[5] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[6] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[7] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[8] Cell Genesys Inc, Foster City, CA USA
来源：
MOLECULAR THERAPY | 2003年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1158
引用
收藏
页码：S446 / S446
页数：1
相关论文
共 35 条
  • [21] Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Milowsky, MI
    Galsky, M
    Lewin, J
    Rozario, CP
    Owens, L
    Marshall, T
    Nanus, D
    Webb, IJ
    Scher, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 406S - 406S
  • [22] CLINICAL RESULTS FROM A PHASE I DOSE ESCALATION STUDY IN TREATMENT-NAIVE EARLY STAGE PROSTATE CANCER PATIENTS WITH ORCA-010, A POTENCY ENHANCED ONCOLYTIC REPLICATION COMPETENT ADENOVIRUS
    Brachtlova, Tereza
    Abramovitch, Allan
    Giddens, Jonathan
    Incze, Peter
    Jansz, Kenneth
    Casey, Richard
    van Beusechem, Victor
    Dong, Wenliang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1004 - A1004
  • [23] Immune enhancement in a phase II clinical trial following infusion of dendritic cells pulsed with prostate-specific membrane antigen-(PSMA) derived peptides into prostate cancer patients.
    Jones, LA
    Lodge, PA
    Tiao, BA
    Bader, RR
    Kelley, HJ
    Ragde, H
    Kenny, RJ
    Rogers, M
    Boynton, AL
    Salgaller, M
    Murphy, GP
    FASEB JOURNAL, 1999, 13 (04): : A301 - A301
  • [24] Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC).
    Milowsky, M. I.
    Galsky, M.
    George, D. J.
    Lewin, J. M.
    Rozario, C. P.
    Marshall, T.
    Chang, M.
    Nanus, D. M.
    Webb, I. J.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 217S - 217S
  • [25] A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses
    Twardowski, Przemyslaw
    Kanaya, Noriko
    Frankel, Paul
    Synold, Timothy
    Ruel, Christopher
    Pal, Sumanta K.
    Junqueira, Maribel
    Prajapati, Manisha
    Moore, Tina
    Tryon, Pamela
    Chen, Shiuan
    CANCER, 2015, 121 (17) : 2942 - 2950
  • [26] Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC)
    Jeske, S. J.
    Milowsky, M. I.
    Smith, C. R.
    Smith, K. A.
    Bander, N. H.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
    Mendez, Lucas C.
    Dhar, Aneesh
    Laidley, David
    Moussa, Madeleine
    Gomez, Jose A.
    Chin, Joseph
    Lee, T-Y
    Thiessen, Jonathan D.
    Hoover, Douglas
    Surrey, Kathleen
    Helou, Joelle
    Velker, Vikram
    Correa, Rohann J.
    D'Souza, David
    Bayani, Jane
    Bauman, Glenn
    BMC CANCER, 2023, 23 (01)
  • [28] Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
    Emmanuel S. Antonarakis
    Michael A. Carducci
    Mario A. Eisenberger
    Samuel R. Denmeade
    Susan F. Slovin
    Kathy Jelaca-Maxwell
    Martha E. Vincent
    Howard I. Scher
    Michael J. Morris
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 763 - 771
  • [29] The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
    Lucas C. Mendez
    Aneesh Dhar
    David Laidley
    Madeleine Moussa
    Jose A. Gomez
    Joseph Chin
    T-Y Lee
    Jonathan D. Thiessen
    Douglas Hoover
    Kathleen Surrey
    Joelle Helou
    Vikram Velker
    Rohann J. Correa
    David D’Souza
    Jane Bayani
    Glenn Bauman
    BMC Cancer, 23
  • [30] Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
    Antonarakis, Emmanuel S.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    Slovin, Susan F.
    Jelaca-Maxwell, Kathy
    Vincent, Martha E.
    Scher, Howard I.
    Morris, Michael J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 763 - 771
1234